ARGX Stock Risk & Deep Value Analysis

argenx SE

Healthcare • Biotechnology

DVR Score

9.1

out of 10

Hidden Gem

The Bottom Line on ARGX

We analyzed argenx SE using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran ARGX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 5, 2025•Run Fresh Analysis →

📈ARGX Performance Overview3yr weekly

📊

Unlock ARGX Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

About argenx SE (ARGX)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

large

Market Cap

$53.63B

ARGX Deep Value Analysis

ARGX demonstrates robust 10x potential driven by its first-in-class FcRn blocker, VYVGART, with a massive addressable market across numerous autoimmune diseases. Strong execution on commercialization and label expansion, coupled with a healthy cash position and expert leadership, solidify its market leadership and competitive moat. While competition is emerging, ARGX's lead, broad pipeline, and clear future catalysts for growth and market expansion provide a strong path to significant returns, mitigating risks of a "dud." The financial trajectory is strong, moving towards profitability driven by increasing sales and a substantial cash runway.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

ARGX Financial Health Metrics

Market Cap

$53.63B

P/E Ratio

36.79

🔔

Never miss a move on ARGX

Create a free account to set price alerts and get notified on Telegram when ARGX hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for argenx SE (ARGX)?

As of September 5, 2025, argenx SE has a DVR Score of 9.1 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of argenx SE?

argenx SE's market capitalization is approximately $53.6B. The company operates in the Healthcare sector within the Biotechnology industry.

What ticker symbol does argenx SE use?

ARGX is the ticker symbol for argenx SE. The company trades on the NMS.

What is the P/E ratio of ARGX?

argenx SE currently has a price-to-earnings (P/E) ratio of 36.8. This is above the market average, suggesting the stock may be priced for high growth expectations.

How often is the ARGX DVR analysis updated?

Our AI-powered analysis of argenx SE is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on September 5, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.